Other researchers have found that inhibition of Cdc42 was responsible for the suppression of invasion ability in lung cancer (Li et al., 2021), while the reduced RhoA had an anti-metastatic function on breast cancer (Kalpana et al., 2021). Here, CDC42 is linked to breast carcinoma.